Eye doctors plead for AMD drug inclusion in basket

Lucentis, approved this week by FDA, is a "revolutionary" treatment against the main cause of blindness.

By
July 5, 2006 00:07
1 minute read.
Eye doctors plead for AMD drug inclusion in basket

eyes 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Leading Israeli ophthalmologists have recommended to the Health Ministry that it include in next year's basket of health service a "revolutionary" new drug, Lucentis, which was approved this week by the US Food and Drug Administration for the treatment of age-related macular degeneration (AMD), the main cause of blindness in the middle-aged and elderly. The drug, which costs about NIS 50,000 a year per patient, is "a real breakthrough," says Prof. Anat Loewenstein, head of the ophthalmology department of Tel Aviv Sourasky Medical Center, who was among those who recommended inclusion of the drug in the basket. A major problem, however, is that Health Minister Ya'acov Ben-Yizri agreed last month that no new drugs would be added to the basket next year because the sum for next year was added to this year's allocation for this purpose. "This is the most important thing in ophthalmology, and maybe in medicine, in the last few decades," Loewenstein told The Jerusalem Post. "It really is a breakthrough - the first time we can give patients back their sight." An article on the Genentech company's drug, to be published in next month's New England Journal of Medicine, states that nearly 40% of AMD patients who took the drug improved their vision significantly during the course of a year. In most of the others, the condition of their eyes remained stable, even if the drug did not improve their vision. There are some 150,000 AMD patients in Israel, 20,000 of whom have the "wet" type of the disease, which puts them at the highest risk for going blind. The disease causes degeneration of the center of the retina, resulting in a large black spot in the center of the field of vision.

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM